menu
    • menu
    [{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sevelamer Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sevelamer Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Sevelamer Carbonate

    Menu

    Sevelamer Carbonate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lupin Ltd

                            India arrow
                            CPhI India 2024
                            Not Confirmed

                            Lupin Ltd

                            India arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sevelamer Carbonate

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lupin Receives Approval from U.S. FDA for Sevelamer Carbonate for Oral Suspension

                            Details : Lupin received approval from the USFDA for its Abbreviated New Drug Application Sevelamer Carbonate for Oral Suspension, which is a generic equivalent of Renvela® for Oral Suspension, 0.8 g and 2.4 g Packets of Genzyme, used to treat increased phosphate...

                            Brand Name : Sevelamer Carbonate-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 25, 2021

                            Lead Product(s) : Sevelamer Carbonate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lupin Ltd

                            India arrow
                            CPhI India 2024
                            Not Confirmed

                            Lupin Ltd

                            India arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sevelamer Carbonate

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lupin Receives Approval for Sevelamer Carbonate Tablets

                            Details : Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.

                            Brand Name : Sevelamer Carbonate-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 25, 2021

                            Lead Product(s) : Sevelamer Carbonate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth